Portfolio Holdings Detail for ISIN IE00BYZK4776

Stock Name / Fund	iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	DRDR(GBX) LSE
ETF Ticker	2B78(EUR) F
ETF Ticker	2B78.DE(EUR) CXE
ETF Ticker	DRDR.LS(GBX) CXE
ETF Ticker	HEAL.AS(EUR) CXE
ETF Ticker	HEAL.LS(USD) CXE
ETF Ticker	HEALz(USD) CXE
ETF Ticker	HEAL(EUR) ETF Plus
ETF Ticker	DRDR.L(GBP) LSE

Holdings detail for ITOS

Show aggregate ITOS holdings

News associated with ITOS

Brokerages Set iTeos Therapeutics, Inc. (NASDAQ:ITOS) Target Price at $15.50

iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Free Report) has received a consensus rating of “Hold” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year target price […] - 2025-08-25 02:44:55

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $15.64 Average Price Target from Analysts

Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Free Report) have received an average recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average […] - 2025-07-31 02:26:51

iTeos Therapeutics (NASDAQ:ITOS) Earns Outperform Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) in a research note published on Monday morning,RTT News reports. They currently have a $10.50 price objective on the stock, down from their previous price objective of $12.00. Several other analysts also recently issued reports on the company. JPMorgan Chase & […] - 2025-07-22 04:30:46

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $15.86 Consensus Price Target from Brokerages

iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Free Report) has been given an average recommendation of “Hold” by the seven research firms that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month price […] - 2025-06-11 02:04:50

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells $388,004.05 in Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Free Report) Director David Hallal sold 38,227 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $10.15, for a total transaction of $388,004.05. The sale was disclosed in a filing with the Securities & Exchange Commission, […] - 2025-06-09 06:10:57

Insider Selling: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells $391,454.72 in Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Free Report) Director David Hallal sold 38,228 shares of the company’s stock in a transaction on Friday, June 6th. The shares were sold at an average price of $10.24, for a total transaction of $391,454.72. The transaction was disclosed in a filing with the SEC, which is available at […] - 2025-06-09 05:32:51

Deutsche Bank AG Sells 14,418 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Deutsche Bank AG cut its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 53.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,531 shares of the company’s stock after selling 14,418 shares during the period. Deutsche Bank AG’s holdings in […] - 2025-06-04 04:54:44

iTeos Therapeutics (NASDAQ:ITOS) Earns “Equal Weight” Rating from Wells Fargo & Company

Wells Fargo & Company reaffirmed their equal weight rating on shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) in a research note published on Wednesday morning, MarketBeat.com reports. They currently have a $12.00 price target on the stock, down from their previous price target of $13.00. ITOS has been the topic of a number of […] - 2025-05-29 03:00:47

Graham Capital Management L.P. Makes New Investment in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Graham Capital Management L.P. purchased a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 11,126 shares of the company’s stock, valued at approximately $85,000. A number of other institutional investors and hedge funds […] - 2025-05-20 05:10:52

iTeos Therapeutics (NASDAQ:ITOS) vs. Molecular Partners (NASDAQ:MOLN) Head to Head Contrast

iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) and Molecular Partners (NASDAQ:MOLN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation. Valuation and Earnings This table compares iTeos […] - 2025-04-30 02:48:54

Russell Investments Group Ltd. Increases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Russell Investments Group Ltd. boosted its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 115.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,225 shares of the company’s stock after purchasing an additional 30,619 shares during the period. Russell Investments […] - 2025-04-24 05:44:48

Renaissance Technologies LLC Grows Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Renaissance Technologies LLC lifted its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 56.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 837,200 shares of the company’s stock after purchasing an additional 300,800 shares during the period. […] - 2025-04-20 05:00:52

Wellington Management Group LLP Raises Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Wellington Management Group LLP grew its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,332 shares of the company’s stock after purchasing an additional 4,563 shares during […] - 2025-04-14 04:50:49

KLP Kapitalforvaltning AS Invests $299,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

KLP Kapitalforvaltning AS bought a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) in the 4th quarter, HoldingsChannel.com reports. The firm bought 38,900 shares of the company’s stock, valued at approximately $299,000. A number of other hedge funds and other institutional investors have also modified their holdings of ITOS. State Street […] - 2025-04-07 04:28:50

Raymond James Financial Inc. Makes New Investment in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Raymond James Financial Inc. bought a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 150,967 shares of the company’s stock, valued at approximately $1,159,000. A number of other institutional investors have also modified their holdings of ITOS. State Street Corp raised its position […] - 2025-04-04 04:44:55

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Purchased by US Bancorp DE

US Bancorp DE increased its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 40.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,919 shares of the company’s stock after acquiring an additional 4,843 shares during the quarter. US Bancorp DE’s […] - 2025-03-17 05:50:52

Wedbush Reaffirms “Outperform” Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS – Get Free Report)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research report issued on Wednesday,RTT News reports. They currently have a $25.00 price objective on the stock. Wedbush’s target price points to a potential upside of 252.61% from the stock’s previous close. ITOS has been […] - 2025-03-07 06:18:59

Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 5.2%

iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Free Report) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,410,000 shares, an increase of 5.2% from the January 15th total of 1,340,000 shares. Based on an average trading volume of 419,500 shares, the short-interest ratio […] - 2025-02-19 06:48:54

iShares Healthcare Innovation UCITS ETF USD (Acc) ITOS holdings

Share Trades of ITOS by Blackrock for IE00BYZK4776

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-08-18	SELL	-148	10.110	10.140	10.137	USD -1,500	8.28 Loss of -274 on sale
2025-08-15	SELL	-148	10.110	10.130	10.128	USD -1,499	8.27 Loss of -274 on sale
2025-08-14	SELL	-147	10.110	10.130	10.128	USD -1,489	8.26 Loss of -274 on sale
2025-07-25	SELL	-146	10.170	10.195	10.192	USD -1,488	8.13 Loss of -302 on sale
2025-07-08	SELL	-145	10.120	10.170	10.165	USD -1,474	7.96 Loss of -320 on sale
2025-06-24	SELL	-151	10.090	10.200	10.189	USD -1,539	7.83 Loss of -355 on sale
2025-06-23	SELL	-151	10.110	10.140	10.137	USD -1,531	7.82 Loss of -350 on sale
2025-06-20	SELL	-9,610	9.960	10.070	10.059	USD -96,667	7.81 Loss of -21,654 on sale
2025-06-11	SELL	-188	10.000	10.060	10.054	USD -1,890	7.70 Loss of -443 on sale
2025-05-30	SELL	-188	10.020	10.130	10.119	USD -1,902	7.56 Loss of -482 on sale
2025-05-21	BUY	189	8.220	8.440	8.418	USD 1,591	7.48
2025-05-14	SELL	-1,134	7.600	8.040	7.996	USD -9,067	7.46 Loss of -610 on sale
2025-04-30	SELL	-187	7.250	7.300	7.295	USD -1,364	7.49 Profit of 37 on sale
2025-04-28	SELL	-187	7.070	7.365	7.335	USD -1,372	7.50 Profit of 31 on sale
2025-04-25	SELL	-187	7.350	7.500	7.485	USD -1,400	7.50 Profit of 3 on sale
2025-04-11	SELL	-1,200	5.650	5.670	5.668	USD -6,802	7.60 Profit of 2,319 on sale
2025-04-08	SELL	-588	5.040	5.404	5.368	USD -3,156	7.67 Profit of 1,356 on sale
2025-04-07	SELL	-400	5.250	5.410	5.394	USD -2,158	7.70 Profit of 922 on sale
2025-03-31	SELL	-388	5.970	6.210	6.186	USD -2,400	7.79 Profit of 621 on sale
2025-03-21	SELL	-380	6.880	6.897	6.896	USD -2,620	7.86 Profit of 368 on sale
2025-03-12	SELL	-200	7.520	7.620	7.610	USD -1,522	7.92 Profit of 63 on sale
2025-02-28	SELL	-201	7.260	7.420	7.404	USD -1,488	8.02 Profit of 124 on sale
2025-02-25	BUY	200	6.980	7.400	7.358	USD 1,472	8.06
2025-02-20	SELL	-201	7.480	7.520	7.516	USD -1,511	8.09 Profit of 116 on sale
2025-02-19	BUY	400	7.500	7.605	7.595	USD 3,038	8.10
2025-02-18	BUY	200	7.440	7.590	7.575	USD 1,515	8.11
2025-01-22	SELL	-194	7.710	8.090	8.052	USD -1,562	8.37 Profit of 62 on sale
2025-01-17	SELL	-195	8.000	8.020	8.018	USD -1,564	8.39 Profit of 73 on sale
2024-12-30	SELL	-379	7.290	7.370	7.362	USD -2,790	8.58 Profit of 461 on sale
2024-12-06	SELL	-183	8.320	8.360	8.356	USD -1,529	8.60 Profit of 45 on sale
2024-12-04	SELL	-183	8.190	8.490	8.460	USD -1,548	8.64 Profit of 33 on sale
2024-12-03	SELL	-368	8.340	8.450	8.439	USD -3,106	8.65 Profit of 78 on sale
2024-11-21	SELL	-196	8.130	8.230	8.220	USD -1,611	8.76 Profit of 106 on sale
2024-11-20	SELL	-201	7.850	8.380	8.327	USD -1,674	8.81 Profit of 98 on sale
2024-11-19	SELL	-201	7.900	7.910	7.909	USD -1,590	8.87 Profit of 193 on sale
2024-11-18	SELL	-756	7.880	8.290	8.249	USD -6,236	8.93 Profit of 514 on sale
2024-11-12	SELL	-188	9.190	9.630	9.586	USD -1,802	8.91 Loss of -127 on sale
2024-11-07	SELL	-187	9.180	9.600	9.558	USD -1,787	8.86 Loss of -130 on sale
2024-11-05	SELL	-374	9.220	9.265	9.261	USD -3,463	8.78 Loss of -179 on sale
2024-10-28	SELL	-189	8.930	8.985	8.979	USD -1,697	8.85 Loss of -24 on sale

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ITOS

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy